Detection of compound mutations is more frequent among CML-BP and Ph+ ALL patients compared to those with CML-CP, thus suggesting an increased risk of compound mutation-based multidrug resistance in advanced disease.[10] Immunotherapy, such as chimeric antigen receptor T-cells therapy, is considered a treatment option with the potential to overcome TKIs resistance based on ABL mutations.[11–13] Unfortunately, the blinatumomab and inotuzumab ozogamicin are not available for Chinese patients because they have still not been approved by CFDA. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.